ClinicaliQ Trial Snapshot
- A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies — Active Not Recruiting • Phase I • Gastroenterology • NCT04606381.
- Testing whether amivantamab can be safely given by injection under the skin instead of intravenously for treating advanced cancers.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to assess the feasibility of subcutaneous (SC) administration of amivantamab based on safety and pharmacokinetics and determine a dose, dose regimen and formulation for amivantamab SC delivery. Conditions: Neoplasms Interventions: Ami-LC-MD, Ami-LC, Ami-HC, Ami-HC-CF Lead Sponsor: Janssen Research & Development, LLC Planned Enrollment: 158 participants